['pulmonary hypertension']
['macitentan', 'placebo']

        Inclusion Criteria:

          1. Males and Females >=18 years of age

          2. Subjects with combined pre-and post-capillary Pulmonary Hypertension (CpcPH) due to
             left ventricular dysfunction (subset of WHO groups 2.1 and 2.2)

          3. Optimized diuretic therapy

        Exclusion Criteria:

          1. Types of Pulmonary Hypertension other than WHO groups 2.1 and 2.2 (Nice
             classification)

          2. Administration of PAH-specific therapy (i.e., Endothelin receptor antagonists (ERAs),
             Prostanoids, Phosphodiesterase 5 (PDE-5) inhibitors, guanylate cyclase stimulators)
      